This inventor holds 3 USPTO granted patents and 8 published patent applications. Top assignees: Secarna Pharmaceuticals Gmbh & Co Kg, Secarna Pharmaceuticals Gmbh & Co. Kg. Active years: 2023-2026.
Company Filing History:
2 out of 3 
1 out of 1 Years Active: 2023-2026
Title: Richard Klar: Innovator in Oligonucleotide Therapeutics
Introduction
Richard Klar is a prominent inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of oligonucleotide-based therapies. With a total of 3 patents, Klar's work focuses on innovative approaches to treat various medical conditions, including cancer.
Latest Patents
Klar's latest patents include groundbreaking inventions that target specific mRNA sequences. One of his notable patents is an oligonucleotide that inhibits the expression of C/EBP-homologous protein (Chop). This invention consists of oligonucleotides comprising 10 to 25 nucleotides, with at least one modified nucleotide. The oligonucleotide effectively hybridizes with the nucleic acid sequence of Chop, inhibiting at least 50% of its expression. Additionally, he has developed antisense oligonucleotides aimed at inhibiting PD-L1 expression, providing a novel approach for cancer treatment by targeting PD-L1 mRNA.
Career Highlights
Richard Klar is currently associated with Secarna Pharmaceuticals GmbH & Co. KG, where he continues to advance his research in oligonucleotide therapeutics. His work has garnered attention for its potential to revolutionize treatment options for patients suffering from various diseases.
Collaborations
Klar collaborates with talented professionals in the field, including his coworker Tamara Thelemann. Their combined expertise contributes to the innovative research and development efforts at Secarna Pharmaceuticals.
Conclusion
Richard Klar's contributions to the field of biotechnology through his patents and research are paving the way for new therapeutic options. His work exemplifies the potential of oligonucleotide-based treatments in addressing critical health challenges.